1. What Is the Radiopharmaceutical Therapy Market?
The Radiopharmaceutical Therapy Market covers therapeutic radioisotopes delivered to tumor cells through targeting molecules enabling internal radiation therapy with cellular precision. Nuclear medicine specialists, radiation oncologists, and specialty cancer centers deploy radiopharmaceutical therapy for prostate cancer, neuroendocrine tumors, and emerging hematological malignancy and solid tumor applications. The market includes Lutetium-177, Actinium-225, Iodine-131, and emerging radioisotope platforms.
2. Radiopharmaceutical Therapy Market Size & Forecast
3. Emerging Technologies
- Tumor antigen-targeted radiopharmaceuticals beyond PSMA and somatostatin receptors expanding the addressable cancer types treatable with targeted radiopharmaceutical therapy.
- Alpha emitter radiopharmaceuticals including actinium-225, thorium-227, and astatine-211 platforms with superior tumor cell kill versus beta emitters.
- AI-powered dosimetry planning optimizing individualized radiopharmaceutical dosing based on patient tumor distribution and healthy tissue radiation exposure.
- Theranostic platforms combining diagnostic imaging and therapeutic radiopharmaceutical pairs enabling precise patient selection and treatment monitoring.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Targeted Cancer Therapy Market.
4. Key Market Opportunity
PSMA-targeted prostate cancer radiopharmaceuticals represent the largest commercial growth opportunity. Novartis Pluvicto expansion to earlier prostate cancer treatment lines creates substantial commercial growth. Neuroendocrine tumor radiopharmaceuticals including Novartis Lutathera represent the largest established commercial category. Actinium-225 alpha emitter pipeline represents the largest long-term opportunity should manufacturing scale-up succeed.
5. Top Companies in the Radiopharmaceutical Therapy Market
The following organisations hold leading positions in the Radiopharmaceutical Therapy Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Novartis
- Lantheus Holdings
- Curium Pharma
- Bayer
- GE HealthCare
- Telix Pharmaceuticals
- Point Biopharma
- Fusion Pharmaceuticals
- Bristol Myers Squibb
- Clarity Pharmaceuticals
6. Market Segmentation
The Radiopharmaceutical Therapy Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Isotope | Lutetium-177 TherapyActinium-225 TherapyIodine-131 TherapyYttrium-90 TherapyRadium-223 Therapy |
| By Indication | Prostate Cancer RadiopharmaceuticalNeuroendocrine TumorsBone MetastasesThyroid CancerHematological Malignancies |
| By Targeting Molecule | PSMA-TargetedSomatostatin Receptor-TargetedCD20-TargetedTumor Antigen-Targeted |
| By End-User | Specialty Cancer CentersNuclear Medicine DepartmentsComprehensive Cancer Centers |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Radiopharmaceutical Therapy Market trajectory over the forecast period:
PSMA-targeted prostate cancer radiopharmaceuticals are driving the fastest commercial growth in the category.Lutetium-177 PSMA-617 represents the most substantial commercial expansion as approved indications expand from late-line to earlier prostate cancer treatment. Novartis Pluvicto demonstrates rapid commercial uptake. The PSMA radiopharmaceutical expansion combined with the substantial prostate cancer patient population is driving substantial sustained commercial growth across PSMA-targeted radiopharmaceutical programs.
Actinium-225 alpha emitter development is emerging as next-generation radiopharmaceutical platform with substantial efficacy advantages versus beta emitters.Alpha particle delivery achieves higher tumor cell kill per radioactive decay with shorter penetration range reducing healthy tissue damage. Actinium-225 production limitations restrain immediate commercial scale but pipeline development is substantial. The alpha emitter advantage is driving systematic pharmaceutical investment in actinium-225 radiopharmaceutical programs.
Supply chain and manufacturing infrastructure investment is critical for radiopharmaceutical commercial growth as short isotope half-lives require sophisticated logistics.Production at limited cyclotron and reactor facilities combined with rapid distribution and patient administration logistics create substantial operational complexity. Novartis, Lantheus, and emerging radiopharmaceutical companies are investing substantially in manufacturing and distribution infrastructure supporting commercial scale-up.
For related market intelligence, see the Cancer Immunotherapy Market.
8. Segmental Analysis
By isotope, the lutetium-177 therapy segment dominated the Radiopharmaceutical Therapy Market in 2025, as Lu-177 in PSMA-targeted prostate cancer and somatostatin receptor-targeted neuroendocrine tumor treatment represents the largest established radiopharmaceutical commercial category sustaining the broadest clinical adoption globally.
By indication, the prostate cancer radiopharmaceutical segment is projected to register the highest growth rate through 2034, as PSMA-targeted radiopharmaceutical expansion to earlier prostate cancer treatment lines combined with substantial pipeline expansion is creating the fastest-growing radiopharmaceutical commercial segment.
9. Regional Analysis
Regional demand patterns across the Radiopharmaceutical Therapy Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Radiopharmaceutical Therapy Market in 2025, accounting for around 48 percent of global revenue. The United States nuclear medicine and prostate cancer treatment infrastructure drives substantial radiopharmaceutical adoption. Novartis Pluvicto and Lutathera generate substantial U.S. commercial revenue. Moreover, U.S. specialty cancer centers and nuclear medicine departments operate the world's most extensive radiopharmaceutical administration infrastructure supporting substantial commercial growth.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Radiopharmaceutical Therapy Market through 2034. European nuclear medicine infrastructure combined with substantial radiopharmaceutical manufacturing capacity creates competitive radiopharmaceutical commercialization environment. Major European countries are systematically expanding radiopharmaceutical treatment capacity. Moreover, European actinium-225 production initiatives and isotope manufacturing investment is driving systematic regional growth in next-generation radiopharmaceutical programs.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Radiopharmaceutical Therapy Market was valued at USD 6.25 Bn in 2025 and is projected to reach USD 21.30 Bn by 2034, growing at a CAGR of 14.6% over the 2026–2034 forecast period.
The Radiopharmaceutical Therapy Market is projected to grow at a CAGR of 14.6% from 2026 to 2034.
North America dominated the Radiopharmaceutical Therapy Market in 2025, accounting for around 48 percent of global revenue.
The leading companies in the Radiopharmaceutical Therapy Market include Novartis, Lantheus Holdings, Curium Pharma, Bayer, GE HealthCare, Telix Pharmaceuticals, Point Biopharma, Fusion Pharmaceuticals, Bristol Myers Squibb, Clarity Pharmaceuticals.
Psma-targeted prostate cancer radiopharmaceuticals are driving the fastest commercial growth in the category.
By isotope, the lutetium-177 therapy segment dominated the Radiopharmaceutical Therapy Market in 2025, as Lu-177 in PSMA-targeted prostate cancer and somatostatin receptor-targeted neuroendocrine tumor treatment represents the largest established radiopharmaceutical commercial category sustaining the broadest clinical adoption globally.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.